Howard A Burris (Howard Burris)

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 9

Top Topics

Dna Damage Response

Top Venues

British journal of cancer

Nature reviews. Clinical oncology

Cancer discovery

This page only lists publications with an associated author ORCID identifier.

Publications

Howard A Burris, Jordan Berlin, Tobias Arkenau, Gregory M Cote, Martijn P Lolkema, Jordi Ferrer-Playan, Anup Kalapur, Jayaprakasam Bolleddula, Giuseppe Locatelli, Thomas Goddemeier, Ioannis Gounaris, Johann de Bono
A phase I study of ATR inhibitor gartisertib (M4344) as a single agent and in combination with carboplatin in patients with advanced solid tumours. British journal of cancer 130 (7) (2024)
Howard A Burris, Jordan Berlin, Tobias Arkenau, Gregory M Cote, Martijn P Lolkema, Jordi Ferrer-Playan, Anup Kalapur, Jayaprakasam Bolleddula, Giuseppe Locatelli, Thomas Goddemeier, Ioannis Gounaris, Johann de Bono
A phase I study of ATR inhibitor gartisertib (M4344) as a single agent and in combination with carboplatin in patients with advanced solid tumours. British journal of cancer (2024)
Howard A Burris, Jordan Berlin, Tobias Arkenau, Gregory M Cote, Martijn P Lolkema, Jordi Ferrer-Playan, Anup Kalapur, Jayaprakasam Bolleddula, Giuseppe Locatelli, Thomas Goddemeier, Ioannis Gounaris, Johann de Bono
A phase I study of ATR inhibitor gartisertib (M4344) as a single agent and in combination with carboplatin in patients with advanced solid tumours. British journal of cancer 130 (7) (2024)
Howard A Burris, Jordan Berlin, Tobias Arkenau, Gregory M Cote, Martijn P Lolkema, Jordi Ferrer-Playan, Anup Kalapur, Jayaprakasam Bolleddula, Giuseppe Locatelli, Thomas Goddemeier, Ioannis Gounaris, Johann de Bono
A phase I study of ATR inhibitor gartisertib (M4344) as a single agent and in combination with carboplatin in patients with advanced solid tumours. British journal of cancer 130 (7) (2024)
Howard A Burris, Jordan Berlin, Tobias Arkenau, Gregory M Cote, Martijn P Lolkema, Jordi Ferrer-Playan, Anup Kalapur, Jayaprakasam Bolleddula, Giuseppe Locatelli, Thomas Goddemeier, Ioannis Gounaris, Johann de Bono
A phase I study of ATR inhibitor gartisertib (M4344) as a single agent and in combination with carboplatin in patients with advanced solid tumours. British journal of cancer 130 (7) (2024)
Justin F Gainor, Manish R Patel, Jeffrey S Weber, Martin Gutierrez, Julie E Bauman, Jeffrey M Clarke, Ricklie Julian, Aaron James Scott, Jessica L Geiger, Kedar S Kirtane, Celine Robert-Tissot, Brandon Coder, Moomal Tasneem, Jing Sun, Wei Zheng, Lauren Gerbereux, Andressa Laino, Filippos Porichis, Jack Pollard, Peijie Hou, Vasudha Sehgal, Xing Chen, Manju Morrissey, Hikmat N Daghestani, Igor Feldman, Lakshmi Srinivasan, Joshua P Frederick, Michelle Brown, Praveen Aanur, Robert Meehan, Howard A Burris
T Cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination With Pembrolizumab in the Phase 1 KEYNOTE-603 Study. Cancer discovery (2024)
Melissa Lynne Johnson, Judy S Wang, Gerald Falchook, Carol Greenlees, Suzanne Jones, Donald Strickland, Giulia Fabbri, Caroline Kennedy, J Elizabeth Pease, Liz Sainsbury, Alexander MacDonald, Stein Schalkwijk, Philip Szekeres, Jan Cosaert, Howard A Burris
Safety, tolerability, and pharmacokinetics of Aurora kinase B inhibitor AZD2811: a phase 1 dose-finding study in patients with advanced solid tumours. British journal of cancer (2023)
Howard A Burris, Arlene Chan, Aditya Bardia, J Thaddeus Beck, Joohyuk Sohn, Patrick Neven, Debasish Tripathy, Seock-Ah Im, Stephen Chia, Francisco J Esteva, Lowell Hart, Juan Pablo Zarate, Antonia Ridolfi, Karen Rodriguez Lorenc, Denise A Yardley
Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer. British journal of cancer 125 (5) (2021)
Howard A Burris
Correcting the ASCO position on phase I clinical trials in cancer. Nature reviews. Clinical oncology 17 (2) (2020)